Breast Cancer Resistance Protein (BCRP), also know as ABCG2, is an ABC transport protein discovered to be a highly specific marker for stem cells. Agents that specifically recognize and/or bind to BCRP are provided, along with methods for using such agents to identify and isolate stem cells. Methods for ex vivo expansion of stem cells modified to express ABC transporters such as BCRP or MDR1 are also provided.
Monoclonal antibody that can recognize BCRP/ABCG2 on the surface of live cells
Granted Patents or Published Applications
U.S. Patent Nos. 6,933,150; 7,622,557; 7,906,331; European Patent No. 1,301,795, Australian Patent No. 2001263496
Related Scientific References
Zhou, S. et al., “The ABC transporter BCRP1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype,” Nature Medicine 7(9): 1028-1034 (2001);
Zhou, S. et al., “Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo,” PNAS 99(19): 12339-12344 (2002);
Abbott, B.L. et al., “Low levels of ABCG2 expression in adult AML blast samples,” Blood 100(13): 4594-2601 (2002);
Tadjali M. et al, "Prospective Isolation of Murine Hematopoietic Stem Cells by Expression of an ABCG2/GFP Allele," Stem Cells Express (Feb. 16, 2006).
We are currently seeking licensing opportunities in all fields for the development of this technology. The BCRP monoclonal antibody has been nonexclusively licensed for sale as a research reagent.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.